key: cord-0797351-auygkmqn authors: Takamatsu, Yuki; Imai, Masaki; Maeda, Kenji; Nakajima, Noriko; Higashi-Kuwata, Nobuyo; Iwatsuki-Horimoto, Kiyoko; Ito, Mutsumi; Kiso, Maki; Maemura, Tadashi; Takeda, Yuichiro; Omata, Kazumi; Suzuki, Tadaki; Kawaoka, Yoshihiro; Mitsuya, Hiroaki title: Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters date: 2021-06-30 journal: bioRxiv DOI: 10.1101/2021.06.29.450453 sha: b5180fbbac31c55e2314b8d9c6a8537e5b5c9130 doc_id: 797351 cord_uid: auygkmqn Despite various attempts to treat SARS-CoV-2-infected patients with COVID-19-convalescent plasmas, neither appropriate approach nor clinical utility has been established. We examined the efficacy of administration of highly-neutralizing COVID-19-convalescent plasma (hn-plasmas) and such plasma-derived IgG administration using the Syrian hamster COVID-19 model. Two hn-plasmas, which were in the best 1% of 340 neutralizing-activity-determined convalescent plasma samples, were intraperitoneally administered to SARS-CoV-2-infected hamsters, resulting in significant reduction of viral titers in lungs by up to 32-fold as compared to the viral titers in hamsters receiving control non-neutralizing plasma, while with two moderately neutralizing plasmas (mn-plasmas) administered, viral titer reduction was by up to 6-fold. IgG fractions purified from the two hn-plasmas also reduced viral titers in lungs than those from the two mn-plasmas. The severity of lung lesions seen in hamsters receiving hn-plasmas was minimal to moderate as assessed using micro-computerized tomography, which histological examination confirmed. Western blotting revealed that all four COVID-19-convalescent-plasmas variably contained antibodies against SARS-CoV-2 components including the receptor-binding domain and S1 domain. The present data strongly suggest that administering potent-neutralizing-activity-confirmed COVID-19-convalescent plasmas would be efficacious in treating patients with COVID-19. Importance Convalescent plasmas obtained from patients, who recovered from a specific infection, have been used as agents to treat other patients infected with the very pathogen. To treat using convalescent plasmas, despite that more than 10 randomized-controlled-clinical-trials have been conducted and more than 100 studies are currently ongoing, the effects of convalescent plasma against COVID-19 remained uncertain. On the other hand, certain COVID-19 vaccines have been shown to reduce the clinical COVID-19 onset by 94-95%, for which the elicited SARS-CoV-2-neutralizing antibodies are apparently directly responsible. Here, we demonstrate that highly-neutralizing-effect-confirmed convalescent plasmas significantly reduce the viral titers in the lung of SARS-CoV-2-infected Syrian hamsters and block the development of virally-induced lung lesions. The present data provide a proof-of-concept that the presence of highly-neutralizing antibody in COVID-19-convalescent plasmas is directly responsible for the reduction of viral replication and support the use of highly-neutralizing antibody-containing plasmas in COVID-19 therapy with convalescent plasmas. Thus, we attempted to quantify the amounts of infectious virions in the lungs of hamsters receiving 214 control-plasma, D43-, D73-, D84-, or D91-plasma samples. Each hamster was exposed to the virus on day each lung was homogenized and the virus titers in the homogenates were determined employing plaque 217 forming assays using VeroE6 TMPRSS2 cells. As shown in Figure 5a , the geometric mean titer for the hamsters 218 receiving control-plasma was 10 8.5 PFU/g, while the administration of D43 and D91 plasmas had 219 significantly suppressed the replication of SARS-CoV-2 UT-NCGM02 with viral titers of down to 10 7.0 220 (p=0.0003) and 10 7.7 (p=0.037) PFU/g, respectively, while the reductions by D73 and D84 plasmas were 221 not statistically significant (p>0.05; Figure 5a ). When IgG fractions isolated from plasmas were 222 intraperitoneally administered to hamsters, D43 IgG fraction gave the greatest reduction with a geometric 223 mean infectious viral titer of 10 7.1 PFU/g compared to the viral titer in the control-plasma-receiving 224 hamsters with a geometric mean titer of 10 8.4 PFU/g; while D91, D84, and D73 IgG fractions gave mean 225 titers of 10 7.7 (p=0.015), 10 7.8 (p=0.037), and 10 8.0 (p>0.05) PFU/g, respectively ( Figure 5b ). In an attempt to see the effects of administering IgG fractions isolated from neutralizing human 227 plasmas on the development of lung lesions in virus-exposed animals, we conducted additional 228 histopathological and immunostaining study. Since we had failed identifying the difference in the 229 histopathological findings among lungs of hamsters receiving various plasmas, we examined the lung in 230 one hamster, which had the lowest infectious viral titer among each group (n=4) in this additional study. We finally attempted to determine which antibodies within the four convalescent D43, D73, D84, and 240 D91 plasma samples bind to SARS-CoV-2 components using the Jess capillary-based Western blot system. The four viral components (RBD, S1, S2, and nucleocapsid) are covalently fixed to the capillary and the 242 presence of human IgG specifically bound to each viral component in the capillary is detected by exposing 243 the capillary to HRP-conjugated anti-human IgG and iridescent light elicited by luminol being mediated by 244 HRP. Figure 6a illustrates that each of the plasma contained IgG antibodies reactive with viral components, showing that the amounts and the ratios of each viral component-specific antibodies were substantially 246 varied. Among the four convalescent plasma tested, D43, one of the two hn-plasmas contained the highest 247 amounts of anti-RBD, -S1, and -NC IgG, while D84 contained the highest amount of anti-S2 and -whole 248 Spike IgG ( Figure 6b ). Interestingly, the two mn-plasmas contained low levels of anti-RBD, -S1, -whole 249 spike and -NC IgG. In the present study, we demonstrate that highly neutralizing COVID-19-convalescent plasmas 254 (hn-plasmas) reduced the severity of lung lesions in SARS-CoV-2-exposed Syrian hamsters compared to 255 those receiving a non-neutralizing (control) plasma or moderately-neutralizing plasmas (mn-plasmas) as One limitation of the current study is that only one SARS-CoV-2 strain (SARS-CoV-2 05-2N ) was 302 employed and the results obtained here may not predict the efficacy in individuals infected with other 303 SARS-CoV-2 strains, in particular, SARS-CoV-2 variants recently isolated [38] [39] [40] [41] , which may escape 304 neutralizing antibodies in plasmas used in the present study 42 or may replicate more efficiently than 305 previously isolated SARS-CoV-2 strains such as SARS-CoV-2 05-2N 43 . However, if convalescent plasmas 306 are collected from individuals who are infected with certain SARS-CoV-2 variants, the plasmas from such 307 individuals should be of use to immediately treat others infected with the same variants. In conclusion, the present data strongly suggest that administering highly-neutralizing 309 COVID-19-convalescent plasmas should be efficacious in treating patients with COVID-19, but potent 310 neutralizing activity has to be confirmed before administering such convalescent plasmas. Figure 1 ). The total dosage and the dosage per body weight of human IgG in 2 ml plasma are shown in Supp. The neutralizing activity of COVID-19-convalescent plasmas and their IgG fractions were determined 536 using MTT assay employing VeroE6 TMPRSS2 cells. The relative amounts of anti-SARS-CoV-2-S1 binding 537 antibody were quantified using anti-SARS-CoV-2-S1 IgG ELISA with serially diluted D84 plasma samples 538 for standardization. All the convalescent plasma and purified IgG showed various potency of neutralizing 539 activity, while healthy donor plasma and its purified IgG were inert against SARS-CoV-2 05-2N . Of note, D43 540 derived plasma and purified IgG showed the most potent antiviral activity with the IC 50 values of 1,400 ± 541 240-fold and 9.2 ± 1.3 μg/ml, respectively. ACTT-2 Study Group Members. Baricitinib plus 671 Remdesivir for Hospitalized Adults with Covid-19 COVID-19: consider cytokine storm syndromes and immunosuppression BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Remdesivir in adults with 690 severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Next generation antibody drugs: pursuit of the 'high-hanging fruit Convalescent plasma or hyperimmune 698 immunoglobulin for people with COVID-19: a living systematic review Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG Fundación 715 INFANT-COVID-19 Group. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development A small molecule 728 compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus 729 replication IgG from COVID-19-convalescent plasma Completely Blocks SARS-CoV-2 Infection Applied regression analysis Targets of T Cell Responses to SARS-CoV-2 Coronavirus 745 in Humans with COVID-19 Disease and Unexposed Individuals Immunological memory to SARS-CoV-2 assessed for up to 8 months 750 after infection WHO 753 International Standard for anti-SARS-CoV-2 immunoglobulin neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 Emergence of a Highly Fit SARS-CoV-2 Variant Genomic characteristics 772 and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome 773 sequencing and hospital-based cohort study Detection of a SARS-CoV-2 variant of concern in South Africa Genomics and 795 epidemiology of the P.1 SARS-CoV-2 lineage in Manaus Neutralization of 798 SARS-CoV-2 Variants B.1.429 and B.1.351